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GENE THERAPY
Engineering human hematopoietic stem/progenitor cells to produce a broadly
neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes
Xin M. Luo,1 Emily Maarschalk,1 Ryan M. O’Connell,1 Pin Wang,2 Lili Yang,1 and David Baltimore1
1Division of Biology, California Institute of Technology, Pasadena; and 2Mork Family Department of Chemical Engineering and Materials Science, University of
Southern California, Los Angeles
Broadly neutralizing anti-HIV antibodies
are rare and have proved hard to elicit
with any immunogen. We have tested in
vitro the notion that such antibodies or
other antiviral proteins could be made by
lentivirus-mediated gene transfer into hu-
man hematopoietic stem/progenitor cells
(HSPCs), followed by differentiation of
the transduced cells into B cells, the most
potent antibody-producing cells. To do
this, we have developed a highly efficient
system for in vitro maturation of secret-
ing B lymphocytes and plasma cells from
CD34 HSPCs. It is a 3-stage, in vitro
culture system that supports normal hu-
man B-lineage development from HSPCs
to antibody-secreting plasmablasts
(36%) and plasma cells (20%). By
transducing human cord blood CD34
cells with lentiviral vectors encoding a
secretory monoclonal anti-HIV antibody,
b12 (IgG1), we were able to program hu-
man B cells to produce in vitro up to
1.5 g/mL of this broadly neutralizing an-
tibody. Our results suggest that an HIV
vaccine might be delivered by autologous
transplantation of in vitro–programmed
HSPCs, which would develop into
antibody-secreting B cells in vivo and pro-
vide a continuous supply of anti-HIV neu-
tralizing antibodies. (Blood. 2009;113:
1422-1431)
Introduction
It is widely agreed that the most effective method to slow the AIDS
epidemic is a vaccine.1,2 However, human efficacy trials of vaccine
candidates designed to elicit either antibody- or T cell–based
immunity have failed.3,4 Elicitation of antibodies is the apparent
mode of protection for most vaccines and would be the mode of
choice for an HIV vaccine. Thus, if a method to produce high titer
HIV-specific neutralizing antibodies in persons at risk for AIDS
could be developed, infection and subsequent disease on exposure
to HIV could be prevented. Because HIV has evolved to be highly
resistant to antibody neutralization5 and all attempts to design an
immunogen that would raise a broadly neutralizing response
have thus far failed,6 a new approach, even a far-fetched one, is
clearly desirable.
One possibility would be to produce an anti-HIV antibody using
protein design methods or in vitro screening. However, were such
an approach to be successful, the protein molecule might be
valuable as a therapeutic but could not be a prophylactic except by
constant administration. But the body’s B lymphocytes are dedi-
cated producers of antibodies, so if they could be programmed to
make a protective antibody, this might prove a valuable asset in
preventing the spread of AIDS. Such a method might also be
valuable for delivering other proteins of therapeutic importance.
Developing such a methodology is a challenge. One would
have to find valuable proteins, know how to program the cells to
make the antibody, preferably have the protective protein made
on demand, be quite certain of the safety of the method, and
make the process cost-effective, particularly in the context of
Africa. We have undertaken this enterprise. We report here our
first successful step, the programming of human B cells to make
a predefined antibody.
For our initial work, we have chosen a known, broadly reactive
human monoclonal neutralizing antibody, b12, one that neutralizes
many primary isolates of different genetic subtypes of HIV-1.7 It
recognizes the CD4 binding site on the viral gp120 glycoprotein.8,9
It has been confirmed that b12 can neutralize clades B, C, and D
primary isolates as tested in vitro7,10 and protect against immunode-
ficiency virus infection in vivo.11,12 B12 variable regions were
originally screened out from a phage-display library,13 and we have
made them into a human IgG1. Because we must work with human
cells, we have chosen to test our procedure using an in vitro culture
system. Although there are systems constructed for in vitro
maturation of murine B cells, there is little work with human
systems and no report of successful engineering of human hemato-
poietic stem/progenitor cells (HSPCs) to generate cells that secrete
significant amounts of a defined antibody. Here, we report the
programming of human B cells to produce more than 1 g/mL of
b12-IgG1 using a 3-stage, in vitro culture system that supports
normal human B-lineage development from HSPCs to antibody-
secreting plasmablasts and plasma cells.
Methods
Plasmid construction
The light and heavy chain variable sequences of b12 were amplified and
inserted upstream of the human  chain constant and secretory IgG1
constant regions, respectively. The 2 resulting genes were linked via F2A14
and subcloned into the FUW lentiviral vector15 to create U-b12. In addition,
we constructed the FMHW lentiviral vector by replacing the ubiquitin-C
promoter in FUW with human  heavy chain promoter preceded by E
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enhancer flanked by matrix association regions (MARs). Similarly, we
constructed the FEEKW vector where the ubiquitin-C promoter was
replaced by human  light chain promoter preceded by enhancers and
MARs. The bicistronic unit of b12 was then subcloned into FMHW and
FEEKW to create MH-b12 and EEK-b12, respectively. For test pur-
poses, we also created vectors expressing green fluorescent protein
(GFP). All constructs were tested in Nalm-6 (pre-B), Ramos (naive B),
Dakiki (plasmacytoma), and Jurkat cell lines before being introduced
into human HSPCs.
Lentiviral transduction
Lentiviruses were generated by transfection of HEK-293T cells through
calcium phosphate precipitation.16 To prepare high-titer viruses, viral
supernatant was concentrated by ultracentrifugation (Optima L-80K ultra-
centrifuge; Beckman Coulter, Fullerton, CA) for 90 minutes at 50 000  g.
Human cord blood CD34 HSPCs were purchased from AllCells (Em-
eryville, CA) and maintained for less than 24 hours before infection in
Iscove modified Dulbecco medium containing 10% fetal bovine serum and
cytokines. The cytokines included human recombinant interleukin-3 (IL-3;
10 ng/mL), Flt3 ligand (10 ng/mL), thrombopoietin (10 ng/mL), stem cell
factor (SCF; 5 ng/mL), and granulocyte-colony stimulating factor (G-CSF;
5 ng/mL) and were given every other day during the infection. All cytokines
were obtained from R&D Systems (Minneapolis, MN) except for Flt3
ligand (eBioscience, San Diego, CA). Two sequential infections of 0.3 to
0.4  106 HSPCs/well by concentrated lentiviral particles at multiplicity of
infection of 1000 were carried out in 48-well plates precoated with
Retronectin (Takara, Kyoto, Japan) at 50 g/mL. HSPCs were collected
3 days after infection and analyzed by flow cytometry. The infected cells
maintained their progenitor phenotype.
In vitro human B lymphopoiesis culture system
Our culture system was extensively modified from the system of Fluckiger
et al17 for better generation of CD19 cells and plasma cells. HSPCs were
first primed for 5 days (stage 1) to commit to B-lineage development in the
presence of IL-3, Flt3 ligand, thrombopoietin, SCF, and G-CSF. MS5 cells
were plated at 3  104 cells/well in 24-well plates overnight. Human
HSPCs transduced with lentiviral vectors or no-virus control cells were
seeded onto the MS5 monolayer at 6  104 cells/500 L per well in Iscove
modified Dulbecco medium containing 5% fetal bovine serum. The
coculture (stage 2) was maintained with biweekly feeding for 5 to 6 weeks,
once with the addition of 500 L of medium and the other time with the
removal of 80% of cells after gentle agitation and adding back 300 L of
medium. After stage 2, cells were counted and seeded at 5  104
cells/500 L per well in 48-well plates precoated with MS5 stably
transduced to express low or high levels of human CD40L on the surface
(MS40L cell lines). The human CD40L clone was obtained from Origene
(Rockville, MD) and subcloned into FUW. MS5 cells were transduced by
FUW-CD40L virus, and MS40L single clones were selected by flow
cytometry to generate MS40L-high and MS40L-low cell lines. Stage 3 was
carried out on the MS40L monolayer for 2 to 3 weeks in the presence of
10 ng/mL of IL-2 (R&D Systems), 100 ng/mL of IL-10 (eBioscience), and
2 M CpG (ODN-2006; synthesized by Integrated DNA Technologies,
Coralville, IA). In some experiments, IL-6 (50 ng/mL; R&D Systems),
soluble CD40L (1 g/mL), and a cross-linking enhancer (2 g/mL; Alexis
Biochemicals, San Diego, CA) were also used.
Enzyme-linked immunosorbent assays
Total human IgM, IgG, and IgA were assayed using commercial enzyme-
linked immunosorbent assays (ELISA) kits (Bethyl Laboratories; Montgom-
ery, TX). The ELISA to detect b12-IgG1 was modified from Selvarajah et
al.18 Briefly, plates were coated overnight at 4°C with monomeric gp120MN
at 2 g/mL in phosphate-buffered saline (PBS). Wells were washed with
PBS containing 0.05% Tween-20 (PBS-T) and blocked with 3% bovine
serum albumin (BSA) for 1 hour at room temperature. After BSA was
aspirated, dilutions of samples and b12 standard in PBS-T containing 1%
BSA were added and incubated at 37°C for 3 hours. The b12 standard
medium was obtained by transfecting 293T cells with U-b12, and its
concentration was determined by Biacore gp120-binding assay (Biacore
T100 biosensor system; GE Healthcare, Little Chalfont, United Kingdom).
Wells were washed again, and goat antihuman IgG F(ab)2 conjugated with
horseradish peroxidase (Pierce Biotechnology, Rockford, IL) diluted 1:1000
was added and incubated for 1 hour at 37°C. Plates were developed by the
addition of 3,3,5,5-tetramethylbenzidine solution (KPL, Gaithersburg,
MD). The reaction was stopped by adding 2 M H2SO4, and plates were read
at 450 nm on a SpectroMax Reader (Molecular Devices, Sunnyvale, CA).
Detection of virus integration
Provirus copy numbers were determined by a modified Alu-long terminal
repeat (LTR) nested-polymerase chain reaction (PCR) protocol.19,20 Briefly,
the first round of PCR allowed the amplification of up to 3 kb between an
Alu sequence (Alu-fw: 5-TCCCAGCTACTGGGGAGGCTGAGG-3) and
a sequence immediately downstream of 5-LTR after the virus is integrated
(PBS-bw: 5-GAGTCCTGCGTCGAGAGAG-3). The second round used
SYBR green-based quantitative PCR (7300 Real-Time PCR system;
Applied Biosystems, Foster City, CA) to detect a 143-bp sequence of the
provirus LTR (late-RT-fw: 5-TGTGTGCCCGTCTGTTGTGT-3; and late-
RT-bw: 5-GAGTCCTGCGTCGAGAGAGC-3). To establish the standard
curve, an integrated gDNA standard was generated by extracting gDNA
from a stable THP-1 cell line with integrated FUW that has been maintained
for 6 months, and the provirus copy number in the standard gDNA was
determined using serial dilutions of linearized FUW plasmid with known
numbers of LTR copies. Genomic DNA of a THP-1 line transduced with an
irrelevant vector was used as the negative control. -Globin was used as the
loading control. The detection range of this Alu-LTR nested-PCR protocol
was 500 to 6  104 copies per 50 ng gDNA. The correlation between the
amount of gDNA and the cell number at different stages of B-cell
development was determined experimentally.
Results
Improvement of the in vitro human B lymphopoiesis culture
system
To produce a system that will support production of a defined
antibody, we first optimized human B-cell generation and antibody
production from unmodified human HSPCs. We used purified
CD34 cells from human cord blood as our starting material,
recognizing that such cell populations are enriched for stem cells
but by no means pure. We call these cells HSPCs to recognize that
the cell population has both stem cells and progenitor cells that
might already be committed to the lymphoid lineage.
During normal hematopoiesis, B-cell populations are generated
from hematopoietic stem cells in the bone marrow and activated to
become plasma cells and memory cells in the periphery/spleen.
Previous murine and human B lymphopoiesis culture systems have
included separate culture stages to mimic the bone marrow and
peripheral/splenic stages of B-cell development, and we followed
that precedent. We summarize here the system we have developed
and its properties. The experimental justification for the statements
made here will be presented when we discuss lentivirally trans-
duced cells. We started with a published human system17 and made
these modifications: (1) We added a step of HSPC priming for
5 days as our stage 1 for B-cell lineage commitment using IL-3 and
Flt3 ligand,21 thrombopoietin,22 and SCF and G-CSF.23 (2) In our
stage 2, murine stromal MS5 cells that provide the B-lineage
growth factor IL-723,24 were used to support the sequential genera-
tion of human pro-B, pre-B, and immature B cells, replacing the
S17 cells used in the previous system. (3) For our stage 3, we
developed a novel cocktail of IL-2, IL-10, and CpG, in conjunction
with transformed MS5 cells providing a low level of anchored
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CD40L (MS40L-low), which supported B-cell activation, replac-
ing the stimulations described in the previous system.17 The growth
factors that promoted B-lineage commitment also facilitated lenti-
viral transduction (data not shown), but they did not further
increase the effect of MS5 on B-cell development and were thus
excluded from stage 2. The improved in vitro human B lymphopoi-
esis culture system is outlined in Figure 1A. In 10 separate
experiments, we found 23% to 28% of pro-B cells after culturing
primed CD34 HSPCs for 3 to 4 weeks on MS5 cells and 65% to
69% of CD19 cells representing a mixture of pre-B and immature
B cells after another 2 to 3 weeks of incubation. Once these cells
were moved to stage 3, within 2 to 3 weeks, 90% of cells were
activated B cells, including antibody-secreting plasmablasts (35%-
37%) and plasma cells (16%-23%). The percentages of B-cell
subpopulations we generated were much higher than previously
reported, where only 5% to 15% of CD19 cells were generated
during the bone marrow stage, and they failed to differentiate into
plasmablasts or plasma cells capable of producing high levels of
antibody,17 indicating that our method provides a more favorable
environment for B-cell development. With this improved human
B lymphopoiesis culture system in hand, we could next test the
concept of using human CD34 cell programming to produce
B cell–based HIV vaccines.
Stage 1 priming for B-lineage commitment and programming of
human B cells through lentiviral transduction of HSPCs
We targeted CD34 cells for B-cell programming because the stem
cell component among these cells could, in the body, provide a
continuous and lifelong supply of programmed B cells. To test viral
transduction, we used a GFP-encoding lentiviral vector, FUGW.15
CD34 cord blood cells were mixed with Retronectin as a bridge
between the virus and the cells. A transduction efficiency of more
than 80% of CD34 cells was achieved after 5 days of incubation in
the priming mixture of factors that support progenitor cell growth
and commitment to the B-cell lineage, namely, IL-3, Flt3 ligand,
thrombopoietin, SCF, and G-CSF (Figure S1A, available on the
Blood website; see the Supplemental Materials link at the top of the
online article). We also found a similar transduction efficiency
when gating on CD34CD38 cells, a rare and particularly
primitive subpopulation of CD34 cells in human cord blood.25
The experimental lentiviral constructs used to produce secretory
b12-IgG1 were created as a bicistronic unit containing secretory 	1
heavy chain and  light chain, bearing, respectively, the heavy and light
variable regions of b12, and the 2 chains were linked by a self-cleaving
F2A peptide14 (Figure 1B). The linked genes were then subcloned into
lentiviral vectors containing either the ubiquitin-C promoter (U) or
B cell–specific promoters (MH or EEK). The latter 2 we produced: the
MH promoter contained E enhancer and MAR upstream of human 
heavy chain promoter, and the EEK promoter consisted of a 3-
enhancer, an MAR, and an intronic enhancer upstream of human  light
chain promoter. When vectors bearing these 3 promoters were trans-
fected into 2 human B-cell lines (Nalm-6 and Ramos) and a T-cell line
(Jurkat), the ubiquitin-driven constructs expressed b12-IgG1 in both B-
and T-cell lines, whereas the B cell–specific promoters led to strong
expression in B cells but little in T cells (Figure S1B). For test purposes,
we also created vectors using these promoters that expressed GFP. In
addition, to confirm the functionality of the b12-IgG1 produced by our
F2A-containing bicistronic lentivectors, we verified the expression and
assembly of b12 heavy and light chains under reducing and nonreducing
conditions (Figure S1C) and the HIV-neutralizing ability of b12-IgG1
using the pseudovirus neutralization assay (Figure S1D).
Stage 2 development of human B cells on MS5 stromal cells
from primed HSPCs
To characterize stage 2, we compared mock-infected CD34 cells
and ones infected with b12-expressing lentiviruses. No differences
were evident. As the cells were incubated with MS5 cells, they lost
CD34 and c-kit, markers for early progenitor cells,26 over the first
Figure 1. Engineering human HSPCs to produce b12, a broadly neutralizing antibody against HIV-1 gp120, after in vitro maturation to B lymphocytes. (A) A 3-stage,
in vitro human B lymphopoiesis culture system was established. Lentiviral constructs were introduced to the HSPCs to achieve B-cell programming. During the 5 days of stage
1, IL-3 (10 ng/mL), Flt3 ligand (Flt3-L; 10 ng/mL), thrombopoietin (TPO; 10 ng/mL), SCF (5 ng/mL), and G-CSF (5 ng/mL) primed the HSPCs for B-lineage commitment. The
6-week stage 2 used stromal support (MS5) and generated a mixture of pre-B and immature B cells from CD34 HSPCs. The 3-week stage 3 promoted B-cell activation,
proliferation, and differentiation into antibody-secreting plasmablasts and plasma cells by the presence of IL-2 (10 ng/mL), IL-10 (100 ng/mL), CpG (2 M), and MS5 cells
stably expressing a low level of CD40L (MS40L-low cells). The surface markers at different stages of B-cell development are shown. (B) Three lentiviral constructs were
generated that carried the secretory form of b12-IgG1 driven by either the ubiquitin-C (U-b12), Ig heavy chain (MH-b12), or Ig light chain promoter (EEK-b12). The MH promoter
contained the human  chain promoter (VHp) preceded by the iE enhancer flanked by matrix association regions (MAR). The EEK promoter contained the  light chain
promoter (VKp) preceded by an intronic enhancer (iE), an MAR, and a 3 enhancer (3E). The secretory 	 (	s) heavy chain and  light chain genes with b12 variable regions
were linked through F2A (2A sequence from foot-and-mouth disease virus) sequences. LTR indicates long terminal repeats; F, HIV-1 flap element; WRE, woodchuck hepatitis
virus posttranscriptional regulatory element.
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3 weeks (Figure S2A). CD13 cells representing the myeloid
lineage started to appear as early as 1 week after the initiation of
coculture (Figure S2B) because the myeloid fate is presumably the
default commitment for HSPCs.27 However, the cooperation of
B-cell lineage priming and MS5 stromal support induced the
generation of CD19 early B cells between weeks 3 and 4 (Figure
2A). Beyond 4 weeks, B cells continued to form and predominated.
The generation of B cells was not affected by transgene expression
(Figure S3A). More importantly, although the ubiquitin promoter
drove similar levels of GFP expression in both CD19 and CD19
cells at 4 weeks, the B cell–specific MH promoter was stronger for
expressing GFP in CD19 cells (Figure 2A right panels).
B-cell development proceeds through multiple, well-characterized
stages.28 CD34 cells lose stem cell markers, rearrange heavy chain
genes, express intracellular heavy chain, and are now pro-B cells. They
then gain expression of surrogate light chains and are pre-B cells. Light
chain genes then rearrange and become surface-IgM immature B cells.
To determine whether stage 2 supported B-cell subpopulations represen-
tative of those present in vivo in normal human bone marrow, we
evaluated the surface expression of early B-lineage markers. Pro-
B cells, identified by CD19 and CD10 coexpression, appeared after
3 weeks (Figure 2B left panels). These cells were negative for the
expression of surrogate light chains, indicating that they were indeed
pro-B cells (data not shown). As anticipated, transgene expression
driven by a B cell–specific promoter was found in pro-B cells but not
other cells (Figure 2B right panels). In contrast, CD11c dendritic cells
derived from MH-GFP–transduced progenitor cells were negative for
GFP (Figure 2C), consistent with the lack of immunoglobulin transcrip-
tion in dendritic cells. This indicates that the MH promoter is predomi-
nantly active in the B-cell lineage.
After 4 weeks of coculture of transduced cells and MS5 stromal
cells, 25% to 30% of total cells were CD19, up from 5% to 8%
at 3 weeks (Figure 2D). At 6 weeks, CD19 cell populations
consisted of VpreB pre-B cells and /
 immature B cells (Figure
2E bottom left and top panels). These cells were , indicating
that they were not mature B cells (Figure 2E bottom right panel).
All CD19 cells were also positive for Ig (Figure 2F), as well as
Ig (data not shown), suggesting that they are capable of signaling
through their B-cell receptor or pre–B-cell receptor. These results
showed that we have sequentially obtained pro-B cells at 3 to
4 weeks and a mixture of pre-B and immature B cells at the end of
stage 2. There was no significant difference in the percentage of
B cells derived among no virus, control vectors (mock or GFP
vectors), or b12 constructs (Figure S3A), and neither MH-b12 nor
EEK-b12 affected the development of CD19CD10 pre-B and
CD19CD10 immature B cells at 6 weeks (Figure S3B),
suggesting that the expression of either a secretory IgG or GFP
does not interfere with normal B-cell development in the bone
marrow. In addition, because the expression of b12 did not block
the appearance of endogenous  heavy chain or /
 light chains
on the cell surface, it is doubtful that the secretory IgG has
allelic excluded endogenous immunoglobulin expression. These
results suggest that HSPCs programmed with a secretory
neutralizing antibody might develop normally into B cells in the
bone marrow.
Figure 2. Stage 2: in vitro development of human B cells on stromal cells. (A) HSPCs primed and transduced with either U-GFP (top panels) or MH-GFP (bottom panels)
lentiviral constructs were cultured on MS5 stromal cells for the indicated periods of time. The cultures were maintained biweekly as described in “In vitro human
B lymphopoiesis culture system.” GFP expression and appearance of CD19 cells were monitored using flow cytometry. (B) Pro-B cells started to appear at 3 weeks of stage 2,
as monitored by the expression of both CD19 and CD10 on the cell surface. When gates were applied to pro-B versus non–pro-B and GFP expression was analyzed in these
gates, the MH promoter showed pro-B cell–specific expression, whereas the ubiquitin promoter did not discriminate between the cells. The lighter lines represent
non–pro-B cells; the darker lines represent pro-B cells. (C) Similar analysis was used to compare CD11c dendritic cells to CD11c cells. (D) Surface  heavy chain was
detected as early as 3 weeks (central panels) into stage 2 and increased at 4 weeks (right panels). The colored labels match the colored lines in the graphs. The percentages
shown are those of total live cells. (E) Expression levels of 
 and  light chains, VpreB surrogate light chain, and  and  heavy chains were plotted against CD19 expression,
indicating a mixture of pre-B and immature B cells at the end of stage 2. The percentages shown are those of total live cells. (F) CD19 cells was positive for Ig at the end of
stage 2 (6 weeks). When both Ig and Ig were examined, the percentage of Ig cells and that of Ig cells was similar. In all analyses, cells carrying EEK-b12 showed a
similar phenotype to those with MH-b12 (data not shown). Unless specified, all fluorochrome-conjugated antibodies were purchased from BD Biosciences PharMingen (San
Diego, CA) or BioLegend (San Diego, CA). Flow cytometry was performed on a BD FACSCalibur System (BD Biosciences, San Jose, CA), and the results were analyzed using
the FlowJo software (TreeStar, Ashland, OR).
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Stage 3 activation and plasma cell differentiation of in
vitro–developed human B cells
To investigate whether the pre-B and immature B cells gener-
ated during stage 2 possess the potential to further develop, we
transferred them to stage 3 for B-cell activation and plasma cell
differentiation. However, as described earlier, the culture condi-
tions for B-cell activation had to be improved because the
previous system17 did not achieve terminal differentiation of
B cells into plasma cells. We extensively tested many stimula-
tory combinations, and the best results are presented here.
Because anchored CD40L might mimic T-cell help for B-cell
activation, we generated 2 stable lines of MS5 origin expressing
high or low levels of human CD40L on the cell surface, named
the MS40L-high or MS40L-low cell lines (Figure 3A). CD40L
expression on T-helper cells is up-regulated through the interac-
tion of T and B cells, and it provides a survival signal for
B cells.29 However, because CD40 ligation also induces apopto-
sis of both normal and malignant B cells,30 we hypothesized that
the strength of CD40 ligation was important and tested whether
the survival and differentiation of in vitro–derived B cells could
be achieved by adjusting the level of anchored CD40L. We
found that the anchorage of CD40L was strikingly beneficial for
the activation and proliferation of B cells compared with soluble
CD40L (Figure 3B) and that MS40L-low cells were better than
MS40L-high for inducing stage 2–derived B cells to become
plasma cells. Plasma cells, which were most evident at the end
of stage 3, were defined by a reduced level of surface CD19 and
IgM (Figure 3C top panels), appearance of CD20CD38 cells
(Figure 3C middle panels), and an increased level of CD27
(Figure 3C bottom panels). These results showed that a suitable
level of anchored CD40L could induce proliferation and termi-
nal differentiation of in vitro–derived B cells into plasma cells.
Figure 3. Promotion of plasma cell differentiation using the MS40L-low cell line along with IL-2, IL-10, and CpG. (A) MS5 cells were transduced by FUW-CD40L virus,
and 2 single-cell clones (MS40L-high and MS40L-low) were selected based on the expression level of CD40L detected by flow cytometry. The shaded peaks represent parental
MS5 cells; open peaks, transduced cells. (B) Stage 2-derived cells carrying the GFP transgene were transferred onto MS40L stable lines (MS40L-high and MS40L-low) and
incubated in the presence of IL-2 (10 ng/mL), IL-10 (100 ng/mL), and CpG (2 M) for 18 days. The ability of MS40L cell lines to support B-cell activation was compared with that
of soluble CD40L (1 g/mL). Soluble CD40L did not support the survival of B cells, leading to nearly no detection of CD19GFP cells. In contrast, the MS40L cell lines
supported the survival and expansion of B cells. (C) The abilities of MS40L-high and MS40L-low to induce plasma cell differentiation were compared as indicated by decreased
CD19 and surface IgM expression (top panels), appearance of CD20CD38 cells (middle panels), and increased CD27 expression (bottom panels). (D) Naive B cells isolated
from human peripheral blood were cultured in the presence of MS40L-low and the indicated stimuli (CpG, IL-2, IL-10, and/or IL-6 [50 ng/mL]) for 9 days and stained for flow
cytometric analysis of plasma cell differentiation (middle panels, CD20CD38 cells; right panels, CD19CD27 and CD19lowCD27/high cells).
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However, antigen-independent activation of naive B cells re-
quires signals in addition to CD40L.31 In one study, this was
achieved with 3 steps of stimulation that included CpG, IL-2,
IL-10, IL-15, IL-6, interferon-, and anti-CD40L.32 By testing
the activation of naive B cells isolated from human peripheral
blood with different stimulatory combinations, we were able to
simplify their cocktail to administration of IL-2, IL-10, and CpG
once every 3 days. The addition of other components of
their cocktail, such as IL-6, did not significantly increase
the percentages of antibody-secreting CD20CD38 and
CD19/lowCD27 cells (Figure 3D). Whether the pre-B and
immature B cells from stage 2 require differentiation into
mature B cells before they were activated requires further
investigation.
A detailed phenotypic evaluation of stage 3 cells cultured for
2 to 3 weeks on MS40L-low in the presence of IL-2, IL-10, and
CpG revealed that antibody-secreting plasmablasts and plasma
cells were generated from our long-term cultures. Plasmablasts
(also called plasma cell precursors) lack CD138 expression33;
however, both precursor and definitive plasma cells produce large
amounts of antibodies. During the differentiation of stage 3 cells,
CD19 expression decreased (Figure 4A left panels), whereas the
percentages of CD20CD38 cells (precursor and definitive plasma
cells) and CD138 plasma cells increased (Figure 4B). CD86
Figure 4. Stage 3: activation and plasma cell differentiation of in vitro–developed human B cells. Cells from stage 2 were transferred onto the MS40L-low monolayer and
incubated in the presence of IL-2 (10 ng/mL), IL-10 (100 ng/mL), and CpG (2 M) for 2 to 3 weeks. (A) Comparison of CD19 expression before (lighter lines) and after (darker
lines) stage 3 showed an increased percentage of CD19 cells but a decrease of CD19 intensity. Expression of CD86 is also shown. (B) Regardless of the promoter (MH or
EEK) and transgene (GFP or b12), both plasmablasts (CD20CD38CD138) and plasma cells (CD20CD38CD138) were generated. The percentages shown are those of
total live cells. (C) Class-switched B cells (surface IgG) and memory B cells (CD19CD27) were also generated. The percentages shown are those of CD19 cells.
(D) B cells from stage 2 proliferated during stage 3 and formed clusters on the MS40L-low monolayer as shown in the phase-contrast and fluorescent images. Bar represents
25 m. Cell clusters were visualized by a Nikon epifluorescence microscope equipped with a GFP filter set (4 objective lens). (E) A representative forward (FSC) and side
(SSC) scatter graph of CD19 cells before (darker traces) and after (lighter traces) stage 3 is shown. The cells after stage 3 were larger in size and more granular than those
before stage 3. (F) Representative Wright stain images of plasmablasts and plasma cells as indicated by arrows. Bar represents 5 m. For Wright stains, single cell
suspensions were cytospinned onto slides, air-dried, stained, and examined on an Olympus BX-51 microscope (10 objective lens) and photographed using a Spot Digital
Camera. (G) Endogenous levels of IgM, IgG, and IgA production by cells carrying no virus or the GFP transgene at the end of stage 2 and stage 3 were assayed using ELISA.
ND indicates not detectable.
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expression was elevated shortly after the initiation of stage 3
(Figure 4A right panels); however, the enhanced level decreased as
B cells switched from proliferating to differentiating into plasma
cells (data not shown). Surface IgG expression appeared, whereas
the percentage of CD27 cells increased (Figure 4C), indicating the
occurrence of class switching of endogenous IgM to membrane-
bound IgG and the appearance of the memory cell phenotype. We
observed no difference between the plasma cell differentiation of
B cells carrying GFP (Figure S4) or b12 lentiviral constructs, and
the effects of MH and EEK promoters on the plasma cell phenotype
did not differ (Figure 4A,B), suggesting that the expression of the
secretory IgG transgene does not interfere with plasma cell
differentiation. Notably, however, the presence of b12 may be
associated with more CD19CD27 memory cells (Figure 4C right
panels). In addition, clusters formed from B cells carrying the
b12-IgG1 transgene were consistently smaller than their GFP
controls (Figure 4D), suggesting that continuous secretion of IgG
may interfere with B-cell proliferation. Nevertheless, B cells at the
end of stage 3 were larger and more granular compared with those
generated from stage 2 (Figure 4E), displayed the morphology of
plasmablasts or plasma cells (Figure 4F; for a histologic compari-
son to normal plasmablasts and plasma cells from human bone
marrow, see Figure S5), and produced large amounts of endoge-
nous IgM, IgG, and IgA (Figure 4G). These results showed that we
can push stage 2-derived B cells to reach the stage of plasmablasts
and plasma cells using a simple combination of IL-2, IL-10, CpG,
and MS40L-low and that these antibody-secreting cells were
phenotypically and functionally normal regardless of the presence
of transgenic b12-IgG1. This indicates that the introduction of a
secretory antibody may not interfere with the peripheral/splenic
stage of normal B-cell development.
Programming of human B cells to produce the broadly
neutralizing anti-HIV antibody, b12-IgG1
Finally, we asked the key question: Can B cells be programmed
through HSPCs to produce the broadly neutralizing anti-HIV
antibody, b12? Analysis of the integrated lentivirus in genomic
DNA of B cells at different times of the in vitro culture system
revealed that the provirus was present throughout B-cell develop-
ment (Figure 5). B cells at the pre-B stage had lower provirus copy
numbers per cell than plasma cells, possibly because of the
outgrowth of nonintegrated pre-B cells. Indeed, the number of
pre-B cells was approximately 2 times that of plasma cells, leading
to lower provirus number at per-cell level. It is probable that the
differentiation process positively selected B cells carrying the
lentiviral integrations. Importantly, the cells carrying the integra-
tions apparently survived and developed, as the provirus copy
numbers per cell at the end of stage 3, on average, were not
statistically different from those of their progenitors (P  .26).
This suggests that stable integration of the lentivirus encoding the
anti-HIV neutralizing antibody can be maintained from HSPCs to
antibody-secreting B cells.
To measure b12 production by B cells in our long-term cultures
and distinguish it from endogenous IgG, we used b12-specific
ELISA to determine the amount of b12 secretion from both stage 2
and stage 3. During stage 2, a small amount of b12-IgG1 was
detected in weekly harvested cell culture supernatants if the b12
transgene had been introduced initially (Figure 6A). The ubiquitin
promoter drove a constantly low level of b12 expression. The
expression of b12 in response to the MH promoter was also low but
probably coincided with the time when pro-B cells started to
appear. Nevertheless, the level of b12-IgG1 secreted during stage 2
was so low that it is unlikely to reach a physiologically relevant
level to neutralize the HIV virus. This suggests that the activation
of B cells carrying b12 may be required for the production of
b12-IgG1 at higher levels because B cells need to be activated to
achieve their full potential as professional antibody-producing
cells. Indeed, when high levels of endogenous IgM, IgG, and IgA
were detected at the end of stage 3 (Figure 6B), we obtained more
than 100 ng/mL of b12 if the cells had been originally transduced
with MH-b12, and a strikingly high level of nearly 1.5 g/mL of
b12 in the case of EEK-b12 (Figure 6C). The capacity of a plasma
cell’s antibody secretion machinery may have limited the total
amount of antibody secreted, leading to the reduction of IgM
production from cells carrying EEK-b12 (Figure 6B), when
b12-IgG was highly produced from these cells (Figure 6C).
Nevertheless, the concentration of 1.5 g/mL achieved by EEK-
b12 is comparable with that of endogenous IgG production and,
when put into human serum, is enough to achieve more than 90%
neutralization of HIV-1 virus in vitro.34 The ubiquitin promoter was
relatively weak for driving transgenes in B cells and thus failed to
induce a level of b12-IgG1 comparable with either of the
2 B cell–specific promoters (data not shown). B12-IgG1 was also
detectable in the cytoplasm of B cells carrying the transgene using
intracellular costainings of fluorochrome-labeled gp120MN and
anti-IgG interacting with the anti-gp120 epitope and 	 heavy chain
constant region of b12-IgG1, respectively (Figure 6D). Collec-
tively, these results showed that, by transducing HSPCs with
MH-b12 or EEK-b12 lentiviral constructs and differentiating the
transduced cells along B-lineage, human B cells can be pro-
grammed to produce the b12-IgG1 neutralizing antibody.
We also asked why the EEK promoter induced a higher level of
transgenic b12 production than the MH promoter. Virus integration
did not differ between the 2 promoters (Figure 6E) as both MH-b12
and EEK-b12 viruses were carefully prepared to ensure equally
efficient transductions. However, we found that the EEK promoter
was more active than the MH promoter in driving GFP expression
in a plasmacytoma cell line (Figure 6F), but not in either Nalm-6 or
Figure 5. Stable integration of the lentivirus maintained throughout human
B-cell development in vitro. Genomic DNA from cells at week 2 and week 4 of stage
2 (representing progenitor and pre-B stages, respectively) and at the end of stage 3
(representing plasma cell stage) was extracted and virus integration was determined
as described in “Detection of virus integration.” Averaged provirus copy numbers per
cell are shown for no virus or different lentiviral constructs originally transduced into
CD34 cells. The results are shown as mean plus SE from combined data obtained
from experiments for the same transgene (vector only, GFP, or b12; regardless of U,
MH, or EEK promoters). There were 5, 3, 6, and 6 biologic replicates for no virus,
vector, GFP, and b12, respectively. The provirus copy numbers per cell at plasma cell
stage, on average, were not statistically different from those of their progenitors
(P  .26). Student 2-tailed t test was performed using Excel statistical software
module (Microsoft, Redmond, WA), and the difference was considered statistically
significant when the P value was less than .05.
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Ramos cell lines (data not shown), suggesting that a light chain
promoter may preferentially drive the expression of b12 in
antibody-secreting plasma cells. This also suggests that plasma
cells are good targets for the engineering of neutralizing antibodies
to be HIV vaccines because of their natural ability to produce large
amounts of antibodies.
Discussion
In this report, we have used the concept of “instructive immuno-
therapy,”35 or “engineering immunity,” to investigate the potential
of a B cell–based anti-HIV vaccination strategy. We showed that
the programming of human B cells to provide neutralizing antibod-
ies as HIV vaccines is achievable through lentiviral transduction of
HSPCs and differentiation of the transduced cells into antibody-
secreting B cells.
To prepare a good in vitro model for our investigation, we
first re-created human B lymphopoiesis in vitro based on the
culture system reported by Fluckiger et al,17 which was modified
extensively to achieve an optimal environment for B-cell
differentiation. Notably, we used a 5-day pretreatment with
IL-3, Flt3 ligand, thrombopoietin, SCF, and G-CSF to commit
HSPCs to the B-lineage development and to provide an environ-
ment for lentiviral transduction before giving the cells stromal
support. In addition, we found a suitable level of anchored
CD40L, provided by the cell line MS40L-low, to mimic T-cell
help for B-cell activation. Furthermore, we found a simple
combination of IL-2, IL-10, and CpG, which, in cooperation
with MS40L-low, could activate B cells and differentiate them
into antibody-secreting plasmablasts and plasma cells. The
improved culture system provided us an excellent tool for
B-cell programming.
Our next obstacle was to find a suitable promoter that could
drive the expression of transgenic b12-IgG1 in antibody-secreting
B cells. Successful cell-specific transgene expression in hematopoi-
etic cells has been achieved for erythroid cells,36 T cells,37 and
B cells.38 For B cells, the CD19 promoter was shown to direct
transgene expression specifically throughout their development in
primary and secondary lymphoid organs.38 Unfortunately, plasma
cells lose the expression of CD19 because of the repression of
B-cell lineage–specific activator protein (encoded by Pax-5) by
B lymphocyte–induced maturation protein-1,39 suggesting that the
strength of the CD19 promoter would be dampened when trans-
duced B cells become plasma cells. Thus, we generated 2 synthetic
promoters (MH and EEK) based on those driving the endogenous
expression of immunoglobulins. Both promoters were capable of
inducing GFP or b12 expression in B cells without affecting B-cell
development.
Figure 6. Programming of human B cells to produce the broadly neutralizing anti-HIV antibody, b12-IgG1. (A) B12 levels during stage 2 were measured using
b12-specific ELISA and are shown by weeks. Note that the culture media were changed biweekly; thus, the data represent the accumulation of the antibody in 3 to
4 days. The results are mean plus or minus SE from 3 independent cultures. * indicates significant difference from week 2 (P  .05). (B) A total of 50 000 cells of each
treatment from stage 2 were transferred to stage 3 of 500 L per well. Total IgM, IgG, and IgA levels were measured, and the results are mean plus SE from
3 independent cultures. “Vector or GFP” represents the averaged effect of empty vectors (FMHW and FEEKW) and GFP-containing vectors (MH-GFP and EEK-GFP).
(C) The levels of b12-IgG1 at the end of stage 3, assayed using b12-specific ELISA, are shown (*P  .02; **P  .002). The bars are color-coded as in panel B.
(D) MH-GFP- or MH-b12-transduced HSPCs were cultured through stage 2 and stage 3, and surface-stained with anti-CD19 antibody and intracellularly stained with
anti-IgG antibody and monomeric gp120. Monomeric gp120MN was labeled using the Alexa-Fluor-647 Protein Labeling Kit from Invitrogen (Carlsbad, CA). Data were
analyzed using flow cytometry and pregated on CD19 cells. Intracellular proteins recognizing gp120 are identified as -gp120. (E) Genomic DNA from progenitor cells
(at week 2 of stage 2) derived from CD34 cells uninfected or infected by MH-b12 or EEK-b12 virus was extracted and virus integration was determined as described in
“Detection of virus integration.” Provirus copy numbers per cell are shown as mean plus SE from 3 independent cultures. (F) Dakiki plasmacytoma cells were transduced
by U-GFP, MH-GFP, or EEK-GFP lentiviruses. Flow cytometry was performed after 72 hours of incubation and the fold of GFP intensity over the effect of U-GFP (defined
as 1) is shown. The difference between MH-GFP and EEK-GFP was significant (P  .05). Student 2-tailed t tests were performed using Microsoft Excel statistical
software module and the difference was considered statistically significant when the P value was less than .05.
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In particular, we found that the EEK promoter was favored for
transgene expression in plasmablasts and plasma cells, giving rise
to a level of 1.5 g/mL of b12-IgG1 production at the end of the in
vitro culture system. Although measured by a different ELISA, the
level of total endogenous IgG was quite similar (1 g/mL). Thus,
the production of total IgG and b12-IgG1 was of the same order of
magnitude, suggesting that the synthetic promoter and the endoge-
nous promoter had comparable strengths. Given that HIV-infected
people have approximately 20 mg/mL of endogenous IgG40,41
(double the usual concentration), if 1% of cells that produce IgG
were transgenic for b12-IgG1, that should yield a serum level as
high as 200 g/mL, well above the level needed for neutraliza-
tion.34,42 Another calculation would be to note that there are
approximately 1012 B cells in a person; and if each made the
1 pg/day of IgG that our cells make in vitro [(1.5 g/mL  0.5
mL)/(50 000 cells  15 days)  1 pg/cell per day], that would
yield 1 g/day of IgG. Because the blood volume is approximately
5 L, that would be a production of 0.2 mg/mL per day. If IgG has a
half-life of 1 month in the blood, that would give a concentration of
3 mg/mL of IgG steady state, within a factor of 3 of the measured
amount in human serum (10 mg/mL). This suggests that our culture
system is producing IgG at a rate comparable with the in vivo rate.
Therefore, our results suggest that HIV vaccination could be achieved
by autologous transplantation of in vitro–programmed HSPCs, which
would develop into antibody-secreting B cells in vivo and provide a
continuous supply of anti–HIV-neutralizing antibodies.
It should be emphasized that the system we present here
represents only a first step to getting a process that will actually
immunize people. For instance, we have used a vector that encodes
only a secretory IgG, but the endogenous system makes first a
membrane-bound immunoglobulin and then a secreted form. Our
system will deliver secretory IgG continuously, but to have a
system like the endogenous one that responds to demand requires a
complicated vector. We are working on several such possibilities.
Best would be a system, like the natural one, that provides allelic
exclusion of the rearrangement of endogenous genes. Another issue that
must be considered is the ability of the virus to escape antibody attack by
mutation, which may necessitate the use of multiple antibodies. If such a
procedure were to be considered for impoverished populations, another
serious limitation would be the cost of the procedure.
Passive transfer of high-titered neutralizing antibodies as vac-
cines has been shown to block simian/HIV infection in ma-
caques42,43 and HIV infection in hu-PBL-SCID mice.11,44 However,
antibodies transferred must remain at high levels to prevent the
establishment of infection. In addition, passive immunization for
HIV has a significant drawback. It would be cost-prohibitive and
impractical to frequently administer antibody preparations to large
numbers of people for an indefinite period of time. In contrast, the
gene therapy method to provide HIV vaccination poses no restric-
tion on the duration of administration or the possibility to deliver
any engineered antibodies or antibody-like proteins that may be
more potent in fighting HIV than natural antibodies. These
engineered molecules include antibodies with enhanced antibody-
dependent cell-mediated cytotoxicity45 and those with dual46 or
even multiple-epitope–binding ability. Our approach uses HSPCs
to provide continuous supplies of such molecules and allows for
predetermination of affinity and specificity before immunization.
Furthermore, certain anti–HIV-neutralizing antibodies have demon-
strated synergy when combined together.47 Thus, the introduction
of several neutralizing antibodies by lentiviral transduction may be
a good strategy to reduce the total amount of antibodies needed to
exert a protective in vivo effect. Finally, the administration of a
mixture of effective antibodies with several specificities is also
valuable for overcoming the development of viral escape mutants.
The HIV virus evolves very rapidly; however, in established
infection of some persons, the continuous exposure to antigen
provides the opportunity for the selection of antibodies capable of
recognizing many viral escape mutants.48 These antibodies, if
administered as a vaccination mixture before the onset of infection,
are clearly beneficial in preventing HIV evolution.
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